TOPLINE:
Dupilumab reduced airway inflammation and mucus burden and enhanced airway volume and flow, which led to better lung function and improved asthma control in patients with moderate to severe type 2 asthma.
METHODOLOGY:
- Researchers conducted a randomized, phase 4 trial at 72 sites across 14 countries from July 18, 2020, to January 6, 2023, to investigate the effectiveness of dupilumab in patients with moderate to severe type 2 asthma.
- Overall, 109 patients (mean age, 50.4 years; 62% women) who were receiving medium- to high-dose inhaled corticosteroids were randomly assigned to either receive add-on dupilumab 300 mg or placebo once every 2 weeks for 24 weeks.
- The primary endpoints were the percentage of patients with a fractional exhaled nitric oxide (FeNO) concentration below 25 parts per billion (ppb) and t he…